The spiraling rise of eating disorders such as bulimia nervosa has elevated in the recent years. Market reports associated with the healthcare sector made accessible by Market Research Future along with published reports on other sectors have been lately put out along with a report on this industry.

The Bulimia Nervosa Market is projected to reach USD 735.8 Million by 2030 at 6% CAGR during the forecast period 2022-2030.

The market is expanding its market share due to rise in the cases being detected mainly due to proper medical diagnosis and increased availability of treatment and options. The market is also considerably influenced by psychological, environmental, and cultural effects. The high focus on body image in contemporary society is also spiking the rate of cases that are being diagnosed. Increased level of investment by companies in the market towards product development and research is anticipated to contribute the market expansion over the forecast period.

Segmental Analysis

The bulimia nervosa market is segmented on the basis of the type of treatment. The segmentation of the market on the basis of the type of treatment comprises of drug therapy, psychotherapy, and others. Psychotherapy is additionally sub-segmented into Maudsley family therapy and others. The drug therapy segment is further sub-segmented into antidepressants and others.

Detailed Regional Analysis 

The North American region leads the region-wise analysis of the bulimia nervosa market. Owing to the growing occurrence of bulimia nervosa in the North American region has expanded the market significantly. The European region has a second major market for the bulimia nervosa. This is because of the government backing and the presence of a well-developed healthcare sector. The Asia Pacific region is anticipated to expand at a rapid rate owing to enormous population base in this region.

Competitive Analysis

The invention in the products and services of the markets will alter the evolution of the market prominently. The market demand and competitors’ tendencies are noticeably improved by the strategies that are being used by market companies. The market is implicitly impacted by the expansions that are occurring in the market.  The actual combination of supply chain management is increasingly enhancing the growth of the market. The chief success factors in the market are easily achieved in the market leading to a raised pace of progress in the forecast period. The long-term feasibility of the market is exceptionally dependent on the techniques and the strategic roadmaps that are engaged by market players. The improved level of focus on the variation of products is growing the number of customers in the market significantly.

The major competitors in the market for bulimia nervosa are Philips Healthcare (U.S), Siemens Healthcare GmbH (Germany), Abbott (U.S), Stryker (U.S), Johnson & Johnson Services, Inc. (U.S), General Electric Company (U.K), Covidien Ltd (Ireland) and Penumbra, Inc. (U.S) among others.

Industry Updates:

Opiant Pharmaceuticals which has the FDA’s approval for extensive use of its proprietary nasal naloxone spray is turning its attention to other addictive disorders such as bulimia nervosa to name a few. The company declared the commencement of a Phase 2 trial of an opioid antagonist (receptor blocking) nasal spray of up to 80 patients in the treatment of the disorder widespread and potentially life-threatening disorder.

Related Report-

Digital Wound Measurement Devices Market Research Report – Forecast to 2027              

Hydrophobic Interaction Chromatography Market Research Report – Forecast to 2027     

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013